Back
News Non classé
1 min read

[Press Release] XAV-19: end of EUROXAV clinical trial and positive trends for the XENOTHERA antibody.

  • Bertrand Fabien
  • Author Bertrand Fabien
  • Published 21 décembre 2022

Related Posts

Reflections on #AACR2024: our key insights and contributions

April, 2024. The AACR Annual Meeting in San Diego was a pivotal...

Read More

XENOTHERA announces the start of the second dose cohort in the FIPO trial

March, 2024. FIPO is the first-in-human trial of XON7, the first anti-solid...

Read More

XENOTHERA : publication of the first-in-human trial of LIS1 in Solid Organ Transplantation

February, 2024. For almost ten years, XENOTHERA has been committed to tackling...

Read More

XENOTHERA

21 rue La Nouë de Fer, 44200 Nantes, France

contact@xenothera.com

Media : xenothera@izsogood.co

Linkedin-in